DDInter605 DDInter899
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Drotrecogin alfa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Alteplase
Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tirofiban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase